MSCs and HCELL molecules track down islet cells and reverse inflammation.
According to a recently published study from the Brigham and Woman’s Hospital, mesenchymal stem cells [MSCs] have the ability to reverse type I diabetes by suppressing the auto-immune attack of islet cells. Although the MSCs cannot be directly injected into the pancreas, the researchers utilized the surface adhesion molecule HCELL to hone the stem cells in on the inflamed islets, allowing them to normalize blood sugar levels without the use of insulin. Continue reading →
CRISPR may change the way scientists incorporate stem cells for translational genomics.
Scientists led by Dr. Craig Mello of The University of Massachusetts have developed a genetic tool – CRISPR [clustered regularly interspaced short palindromic repeats] – to revolutionize the way stem cells are applied to treat genetic diseases, such as sickle cell or thalassemia. CRISPR aims to expedite and improve upon the process of translational genomics, in which the patient’s stem cells are extracted, altered to repair the damaged gene, and then transplanted back to the patient. Continue reading →
The transplantation of adult stem cells into a Type-1 Diabetes animal model has revealed the importance of blood vessels in pancreatic beta cell regeneration.
Researchers led by Dr. Habib Zaghouani from the University of Missouri have developed a potential cure to Type 1 Diabetes by utilizing mesenchymal stem cells [MSCs]. Although researchers anticipated that the MSCs would differentiate into new insulin producing pancreatic beta cells, they discovered that the stem cells fulfilled the more critical function of repairing damaged blood vessels, which in turn facilitated the regeneration of insulin producing pancreatic beta cells and the distribution of insulin across the body. Continue reading →
Stem cells have been differentiated into pancreatic beta cells, providing a potential treatment for Type 1 Diabetes.
Researchers from the Gladstone Institutes have developed a potential treatment for Type 1 diabetes by differentiating stem cells into insulin-producing pancreatic beta cells. These new cells, when transplanted into animal models, lowered abnormally high glucose levels down to a more healthy level in just one week. Continue reading →
The ability to grow intestinal stem cells creates the possibility of personalized treatments for intestinal disease.
Researchers at MIT and Brigham and Women’s Hospital have developed a method of growing unlimited quantities of intestinal stem cells thus enabling them to better understand intestinal diseases and advance the development of more personalized and effective treatment options. Continue reading →
Saving stem cells in cord blood ensures access to emerging regenerative therapies.
As reported by the Wall Street Journal, adult stem cell therapies are advancing rapidly; with researchers utilizing stem cells to treat an expanding range of disease, trauma and injury. The article highlights the increasing use of cord blood to treat a variety of ailments such as; Cerebral Palsy, Traumatic Brain Injury and immune deficiencies such as diabetes. Continue reading →
In an early stage study recently carried out by the Institute of Kidney Diseases and Research Center (IKDRC), a treatment developed by the IKDRC utilizing Insulin Secreting Cells (ISC), derived from the patient’s own mesenchymal stem cells, shows that the need for insulin doses decreased by an average of 50% when the ISCs were implanted in patients.
Millions of individuals around the world suffer from type-1 diabetes, three million in the US alone. Researchers at the University of Missouri, led by Dr. Habib Zaghouani, have developed a two pronged approach to curing the disease: they modulate the immune system with a drug that stops it from attacking the pancreas and use stem cells to regenerate and rebuild the insulin producing pancreatic beta cells.